Status:
COMPLETED
Lapdap and Coartemether for Uncomplicated Malaria
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
Medical Research Council
National Malaria Control Programme, The Gambia
Conditions:
Malaria
Eligibility:
All Genders
6-10 years
Phase:
PHASE3
Brief Summary
Lapdap (chlorproguanil-dapsone) is an affordable and effective drug, but patients with glucose-6-phosphate dehydrogenase (G6PD) A- deficiency are more susceptible to the haemolytic effects of the daps...
Detailed Description
Patients with uncomplicated malaria will be recruited at three health centres in the Gambia. Children aged 6 months to 10 years presenting with a history of illness, who have a fever or recent history...
Eligibility Criteria
Inclusion
- presentation at health centre with febrile illness
- monoinfection with P falciparum
- parasitaemia \>=500/microlitre
- fever or history of fever
Exclusion
- signs of severe or complicated malaria (persistent vomiting with or without dehydration, history of convulsion during the present illness, inability to sit or stand, parasitaemia \>200,000/ul)
- severe malnutrition
- clinically evident concomitant disease
- PCV \<20%
- history of allergy to the study medications
- residence outside the study area and hence difficult to follow up
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00118794
Start Date
September 1 2004
End Date
June 1 2005
Last Update
February 1 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Research Council Laboratories
Banjul, City of Banjul, The Gambia, POBOX273